Loading
A phase 2 trial of Izalontamab brengitecan, Pembrolizumab, Bevacizumab in cervical cancer and endometrial cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer is a phase 2 interventional study registered as NCT07054567 by Sichuan Baili Pharmaceutical Co., Ltd., with 96 participants planned, started 2025-08-21 and due to reach its primary completion in 2027-05. Interventions recorded: BL-B01D1, Pembrolizumab, Bevacizumab. Conditions listed: Cervical Cancer, Endometrial Cancer. No results are recorded here; the registry entry is the source.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Anti-angiogenic therapy, Cervical cancer.
Shares Izalontamab brengitecan, Recurrent or metastatic cervical cancer, SystImmune / Sichuan Biokin, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Anti-angiogenic therapy, Cervical cancer.
Shares Advanced or recurrent endometrial cancer, Anti-angiogenic therapy, Endometrial cancer, Monoclonal antibodies.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced or recurrent endometrial cancer, Anti-angiogenic therapy, Endometrial cancer, Monoclonal antibodies.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Cervical cancer, Pembrolizumab.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Pembrolizumab, Immune checkpoint inhibitors.